Sanofi Reports Positive Phase 3 Atopic Dermatitis Data Sanofi said on Mar 28, 2026 its Phase 3 (n≈1,250) met the primary endpoint with ~64% achieving EASI-75 vs 18% placebo at Week 16 (Investing.com); full data pending.

Sanofi Reports Positive Phase 3 Atopic Dermatitis Data: Sanofi said on Mar 28, 2026 its Phase 3 (n≈1,250) met the primary endpoint with ~64% achieving EASI-75 vs 18% placebo at Week 16 (Investing.com); full data pending. 👈 Read full analysis #Sanofi #AtopicDermatitis #Phase3 #ClinicalTrials #EASI75